TY - JOUR. T1 - Acute cellular rejection following human heart transplantation is associated with increased expression of vitronectin receptor (integrin αvβ3). AU - Yamani, Mohamad H.. AU - Yang, Jiacheng. AU - Masri, Carolyna S.. AU - Ratliff, Norman B.. AU - Bond, Meredith. AU - Starling, Randall C.. AU - McCarthy, Patrick. AU - Plow, Edward. AU - Young, James B.. PY - 2002/2. Y1 - 2002/2. N2 - The vitronectin receptor (integrin αvβ3), a cell-surface adhesion receptor, has been shown to play a significant role in endothelial cell migration, apoptosis, atherosclerosis, and T-lymphocyte activation. This study was undertaken to test the hypothesis that cardiac allograft rejection is associated with increased expression of αvβ3. We also determined whether fibronectin receptor (α5β1) and tissue factor are up-regulated in the presence of acute cellular rejection. We evaluated endomyocardial biopsy specimens with histologic evidence of different degrees of acute cellular rejection (grade 0, n ...
were present in biopsies from patients with subclinical rejection and largely absent in normal protocol biopsies. Transcripts for perforin, Fas ligand, and granzyme B were also present in patients with subclinical rejection, although in reduced amounts when compared to biopsies from patients with clinical rejection episodes. There were no differences in IL-10 and IL-15 transcripts in clinical and subclinical rejection biopsies. Additional, albeit indirect, data in favor of a pathogenic role for subclinical rejection comes from the early observation of Isoniemi et al, who reported that in patients who had not experienced clinical acute rejection episodes, the development of chronic histological changes occurred in inverse relation to the amount of immunosuppression they had received.15 Similarly, Legendre et al reported a patient cohort that never experienced clinical rejection episodes, in whom the development of chronic rejection at 2 years was preceded by subclinical rejection at three ...
TY - JOUR. T1 - Sero-molecular evaluation of human cytomegalovirus disease in renal transplant rejection.. AU - Kishore, Janak. AU - Mukhopadhyay, Chiranjoy. AU - Savitri, AU - Ayyagari, Archana. AU - Sharma, Rakesh Kumar. PY - 2004/1/1. Y1 - 2004/1/1. N2 - Cytomegalovirus (CMV) is the most common viral pathogen in renal transplant recipients resulting in graft rejection. The prevalence of CMV disease and renal graft rejection is not well studied in India. Sequential specimens from 32 renal allograft recipients were examined by using CMV IgM specific mu capture ELISA and DNA by PCR. Twelve of the 32 patients were CMV IgM positive and out of 12 patients, 9 had rejection and 4 experienced CMV disease. CMV IgM specific mu capture ELISA helped in diagnosis of CMV disease, though it is less sensitive in detection of rejection. PCR itself was proved not sensitive enough in detecting either CMV disease or rejection. At present, optimal laboratory detection of CMV infection in these patients can be ...
Chronic renal transplant rejection is a form of renal transplant rejection. It usually later following transplantation. Pathology Chronic rejection is defined as a gradual deterioration in graft function beginning at least 3 months after transp...
A graft vessel preparation device and a method for using the graft vessel preparation device is provided. The graft vessel preparation device establishes and maintains a critical dimension on a graft vessel which corresponds to a dimension of an anastomosis site on a target vessel. One example of a graft vessel preparation device which prepares a graft vessel for a vascular anastomosis procedure includes a parallelogram linkage, a first spreader arm and a second spreader arm. The first spreader arm and the second spreader arm mount on opposing members of the parallelogram linkage in a parallel configuration. The spreader arms are configured in order to allow the placement of an end of a graft vessel over the spreader arms. The spreader arms are also configured to separate within an interior of the graft vessel once the graft vessel is placed over the spreader arms in order to establish a critical dimension. The critical dimension is established using a critical dimension locator. The critical dimension
Renal graft failure due to chronic rejection, also known as chronic allograft nephropathy, is one of the leading causes for repeat renal transplantation. Chronic rejection is characterized by progressive fibrosis and scarring. Renal biopsies of patients undergoing chronic rejection show greater expression of profibrotic cytokines, including TGF-beta and PDGF, than normal kidney tissue. Moreover, the cytokine activity of chronic rejection resembles that of other fibrosing renal diseases. Angiotensin converting enzyme inhibitors (ACEinh) and HMG-CoA reductase inhibitors have been shown to protect effectively against other types of fibrotic disease. These drugs may protect against fibrosis and preserve renal function in renal transplant patients with chronic rejection, in part by blocking activation of TGF-beta and PDGF. This study evaluates the impact of irbesartan (an AII-RB which acts similar to an ACEinh) and pravastatin on the clinical progression of chronic rejection and on the expression of ...
BACKGROUND: The potential therapeutic benefits of CD3 monoclonal antibodies, such as OKT3, have been limited by their immunogenicity and their propensity to activate a severe cytokine release syndrome. This has constrained the clinical use of OKT3 to the treatment of acute rejection episodes of organ allografts. METHODS: We have humanized a rat CD3 antibody and created a single amino acid substitution in position 297 of the IgG1 heavy chain to prevent glycosylation and, consequently, binding of the therapeutic antibody to Fc receptors and to complement. This antibody has been given as first line antirejection therapy in nine kidney transplant recipients with biopsy-proven acute rejection episodes. RESULTS: None of the patients demonstrated any antiglobulin response nor any significant cytokine release syndrome. Seven of the nine showed evidence of resolution of their rejection, although some patients experienced re-rejection. CONCLUSIONS: These findings suggest that CD3 antibodies can be engineered to
Looking for Antibody-Mediated Rejection? Find out information about Antibody-Mediated Rejection. Destruction of a graft by the immune system of the recipient. Rejection in a dream may suggest that there are feelings or situations the dreamer wants to be... Explanation of Antibody-Mediated Rejection
BACKGROUND Although many risk factors are reported about graft rejection after heart transplantation (HTx), the effect of HLA mismatch (MM) still remains unknown, especially in the Japanese population. The aim of the present study was to investigate the influence of HLA MM on graft rejection among HTx recipients in Japan. METHODS We retrospectively investigated the association of the number of HLA MM including class I (A, B) and class II (DR) (for each locus MM: 0 to 2, total MM: 0 to 6) and the incidence of moderate to severe acute cellular rejection (ACR) confirmed by endomyocardial biopsy (International Society for Heart and Lung Transplantation grade ≥ 3A/2R) within 1 year after HTx. RESULTS Between 2007 and 2014, we had 49 HTx cases in our institute. After excluding those with insufficient data and positive donor-specific antigen, finally 35 patients were enrolled. Moderate to severe ACR was observed in 16 (45.7%) patients. The number of HLA-DR MM was significantly associated with the
Background: Regulatory T cells have been suggested to have a protective role against acute rejection in allograft recipients. However, there is little information available about their contribution to chronic rejection process. The role of transforming growth factor-beta 1 (TGF- β1) as a profibrogenic and/or immunoregulatory cytokine in renal allografts is also controversial. Objectives: To evaluate the frequency of CD4+CD25+CD127- and CD3+CD8+CD28- regulatory T cells in chronic allograft dysfunction (CAD) and to investigate the expression of TGF- β1 in renal allografts. Methods: Thirty biopsy-proven CAD patients were pair-matched with 30 stable graft function patients and a third group of healthy volunteers. Flowcytometry was performed on PBMCs to determine the frequency of CD3+CD8+CD28- and CD4+CD25+CD127- regulatory T cells in lymphocyt population. TGF- β1 gene expression was assessed by Real Time PCR. Results: The percentage of CD3+CD8+CD28- Tregs among renal allograft recipients was higher than
Background: Predisposing factors, long-term occurrence, and histopathological changes associated with recovery or progression to allograft failure from chronic rejection (CR) were studied in adult patients treated primarily with tacrolimus. Methods: CR cases were identified using stringent criteria applied to a retrospective review of computerized clinicopathological data and slides. Results: After 1973 days median follow- up, 35 (3.3%) of 1049 primary liver allograft recipients first developed CR between 16 and 2532 (median 242) days. The most significant risk factors for CR were the number (P,0.001) and histological severity (P,0.005) of acute rejection episodes and donor age ,40 years (P,0.03). Other demographic and matching parameters were not associated with CR in this cohort. Ten patients died with, but not of, CR. Eight required retransplantation because of CR at a median of 268 days. Ten resolved either histologically or by normalization of liver injury tests over a median of 548 days. ...
TY - JOUR. T1 - The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss. AU - Schinstock, Carrie. AU - Cosio, Fernando G. AU - Cheungpasitporn, W.. AU - Dadhania, D. M.. AU - Everly, M. J.. AU - Samaniego-Picota, M. D.. AU - Cornell, L.. AU - Stegall, Mark D. PY - 2017/6/1. Y1 - 2017/6/1. N2 - De novo donor-specific antibody (dnDSA) is associated with antibody-mediated rejection (AMR) and allograft loss, yet the allograft histology associated with dnDSA remains unclear. The aim of this study was to examine the allograft histology associated with dnDSA in patients with serial surveillance biopsies. We retrospectively studied adult conventional solitary kidney transplant recipients from October 2007 to May 2014. The definition of dnDSA was new donor-specific antibody (DSA) with mean fluorescence intensity (MFI) ,1000. The incidence of dnDSA was 7.0% (54 of 771) over mean follow-up of 4.2 ± 1.9 years. Patients with dnDSA had reduced ...
The aim of our study was to investigate the expression of kidney injury molecule-1 (KIM-1) in renal allograft biopsy samples and assess the clinical significance of its use as a biomarker for tissue damage. A total of 69 renal allograft biopsy samples from 17 patients with normal serum creatinine and 52 cases of increased serum creatinine were collected. They were divided into different groups according to the Banff 2007 diagnostic criteria. KIM-1 expression was detected by immunohistochemical methods and the association of KIM-1 and blood biochemical indexes was analyzed. KIM-1 expression increased as Banff 2007 classification grade increased and was positively correlated with tubular inflammation severity in the acute T-cell rejection group. Moreover, KIM-1 expression was strongly positive in the chronic active antibody-mediated rejection group. Interestingly, KIM-1 was weakly positive in the normal group without obvious acute rejection and injury of immunosuppressant toxicity. In this group, ...
Synonyms for Chronic rejection in Free Thesaurus. Antonyms for Chronic rejection. 41 synonyms for rejection: refusal, turning down, declining, dismissal, spurning, rebuff, knock-back, non-acceptance, denial, veto, dismissal, exclusion.... What are synonyms for Chronic rejection?
Sigma-Aldrich offers abstracts and full-text articles by [Thomas Bachelet, Celine Nodimar, Jean-Luc Taupin, Sebastien Lepreux, Karine Moreau, Delphine Morel, Gwendaline Guidicelli, Lionel Couzi, Pierre Merville].
In their paper published in this issue of Heart, Goland et al provide novel insights into changes in function of the transplanted heart within the first year (see page 1681).1 This paper, together with a recent article also published in this journal,2 contribute greatly in illuminating a field in which physiological investigation has been largely uncharted.. After the first heart transplant was performed by Christiaan Barnard in 1967, success was variable until immunosuppressive regimens were perfected.3 With these measures, and improved understanding of the immunology of rejection, the incidence of hyperacute allograft failure, largely due to hyperacute rejection, has become rare.4 However, acute rejection is still a concern, although its incidence decreases with time after transplantation5 most probably owing to the development of immune tolerance. Chronic rejection is a more difficult problem as it follows an insidious course. The histological hallmarks of chronic rejection in the ...
We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time.Find out more ...
Kidney transplantation is the best treatment for many patients with kidney failure. Sometimes a transplanted kidney is rejected by the patients immune system. Many types of immune system cells, including B cells, are active in rejection. B cells produce antibodies against anything the body sees as non-self, like germs or a transplanted kidney. Most medicines that help prevent transplant rejection affect cells other than B cells. Belimumab is a medication used to treat a disease called lupus. Belimumab slows development of antibody-producing B cells. This study will test whether belimumab works on parts of the immune system that cause rejection. Twenty to thirty adults getting a kidney transplant will be in this study. Like flipping a coin, a computer will randomly assign half to be given belimumab and half to be given placebo (a fake medicine). Patients and doctors will not know which medicine was assigned until the study is over. A total of 7 doses of study medicine will be given through a ...
A method of diagnosing cardiac transplant rejection within a patient comprising, obtaining a sample of a biological fluid from the patient, and determining the level of a brain natriuretic peptide (BNP) or a fragment thereof, within the sample of body fluid. The step of determining the concentration of BNP involves an assay comprising at least one antibody exhibiting affinity for the BNP or a fragment thereof, and the biological fluid comprises plasma, urine or cerebrospinal fluid. Furthermore, the antibody used within the method may comprises a polyclonal antibody, a monoclonal antibody, or a combination thereof. Preferably, the method involves obtaining at least two of the samples of body fluid from the patient over a period of time and comparing the BNP levels, with an increase in BNP being indicative of an upcoming rejection episode.
A simple, inexpensive blood test could soon help doctors halt organ rejection before it impairs transplanted hearts and kidneys.. "In the past, we couldnt spot rejection episodes until they harmed the organ," said Atul Butte, MD, PhD, who is co-senior author of the new research and an associate professor of medical informatics and of pediatrics at the Stanford University School of Medicine, in addition to director of the Center for Pediatric Bioinformatics at Lucile Packard Childrens Hospital. "Our goal is to develop blood tests that will keep transplanted organs functioning so that patients can avoid a second transplant.". Butte and his collaborators have made a big step toward that goal. The Stanford team found three easily measured proteins that rise in the blood during acute rejection, in which a patients immune system attacks his or her transplanted organ. The research, which will be published online Sept. 23 in PLoS-Computational Biology, is the first-ever report of an immune-rejection ...
Thank you for your interest in spreading the word about The Journal of Immunology.. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.. ...
For decades, immunologists have been trying to train the transplant recipients immune system to accept transplanted cells and organs without the long-term use of anti-rejection drugs. New University of Minnesota preclinical research shows that this is now possible.. In a study published in Nature Communications, researchers at the University of Minnesota Medical Schools Department of Surgery and Schulze Diabetes Institute, collaborating with colleagues at Northwestern University, have maintained long-term survival and function of pancreatic islet transplants despite complete discontinuation of all anti-rejection drugs on day 21 after the transplant. This study was performed in a stringent preclinical transplant setting in nonhuman primates, one step away from humans.. For many patients with end-stage organ failure, transplantation is the only effective and remaining treatment option. To prevent transplant rejection, recipients must take medications long-term that suppress the bodys immune ...
Addressing the etiological heterogeneity of interstitial fibrosis in kidney allografts represents an important challenge to improve long-term transplant outcomes. We investigated the determinants, clinical and histological phenotype, and outcome of i-IF/TA in a prospective cohort of kidney recipient
In a study published in Nature Communications, researchers at the University of Minnesota Medical Schools Department of Surgery and Schulze Diabetes Institute, collaborating with colleagues at Northwestern University, have maintained long-term survival and function of pancreatic islet transplants despite complete discontinuation of all anti-rejection drugs on day 21 after the transplant. This study was performed in a stringent preclinical transplant setting in nonhuman primates, one step away from humans.. For many patients with end-stage organ failure, transplantation is the only effective and remaining treatment option. To prevent transplant rejection, recipients must take medications long-term that suppress the bodys immune system. These immunosuppressive drugs are effective at preventing rejection over the short term; however, because anti-rejection drugs suppress all of the immune system nonspecifically, people taking these drugs face the risk of serious infections and even cancer. ...
Predicting liver transplant rejection The survival rate of liver transplant patients one year after treatment has improved from about 30 in the 1970s to more than 80, with acute cellular rejection ACR the most common complication. It occurs in about 30 of cases and is generally arrested by drug treatment. However, if ACR occurs more than one year...
Oxford University scientists in the UK have shown that a powerful drug given at the time of a kidney transplant operation not only halves the early risk of rejection, but that it also allows a less toxic regimen of anti-rejection drugs to be used after the operation.
Lipocalin 2 (Lcn2) is rapidly produced by damaged nephron epithelia and is one of the most promising new markers of renal injury, delayed graft function and acute allograft rejection (AR);however, the functional importance of Lcn2 in renal transplantation is largely unknown. To understand the role of Lcn2 in renal AR, kidneys from Balb/c mice were transplanted into C57Bl/6 mice and vice versa and analyzed for morphological and physiological outcomes of AR at posttransplantation days 3, 5, and 7. The allografts showed a steady increase in intensity of interstitial infiltration, tubulitis and periarterial aggregation of lymphocytes associated with a substantial elevation in serum levels of creatinine, urea and Lcn2. Perioperative administration of recombinant Lcn2:siderophore:Fe complex (rLcn2) to recipients resulted in functional and morphological amelioration of the allograft at day 7 almost as efficiently as daily immunosuppression with cyclosporine A (CsA). No significant differences were ...
Rejection is a risk of transplantation. The phenomenon is usually caused by a reaction of the recipients immune system vis-à-vis the transplant, which it considers an invader. HLAs (human leucocyte antigens), which are present on the surface of all cells, are a sort of unique identifier for each person. In transplants, doctors try to avoid rejection by ensuring that the donor and recipient are compatible with regard to blood group and HLA antigens. Despite these precautions, one in ten transplants results in rejection. To solve this mystery, the researchers focused on blood vessels, an important component in transplantation. When blood vessels are damaged, rejection is more difficult to treat. "We discovered that the damaged blood vessels release specific bits of cells: small membrane vesicles that put the immune system on alert. If we then perform a transplant, the immune system immediately attacks the donor organ," said Melanie Dieudé, a researcher at the CRCHUM and first author of the ...
Failed Allografts. The reasons for liver allograft failure vary with the time since transplantation(1-6). Primary dysfunction because of ischemic/preservation injury and hepatic artery thrombosis and subsequent bile duct necrosis are the most common causes of liver within the first several weeks. Humoral and severe acute cellular rejection also occur during this time, but they are uncommon causes of early allograft failure. Frequently, a combination of the above factors ultimately contribute to deterioration of graft function(1-6). Between 2-3 weeks and 6 months after transplantation, delayed complications of early technical problems, such as the biliary sludge syndrome from ischemic cholangitis(7, 8), acute rejection and rapidly developing cases of chronic rejection(9, 10) are the major causes of graft failure. There are still graft failures that occur more than 6 months after transplantation, as a result of delayed technical complications. These usually involve the hepatic artery and ...
Basiliximab is a monoclonal interleukin-2 receptor antagonist commonly used for induction immunosuppression in lung transplantation. This single centre retrospective review of 119 patients transplanted between 1994 and 2009 examined the impact of the timing of basiliximab dosing on the frequency and severity of acute rejection, the development of BOS, and overall survival. Pre-implantation administration of […]. ...
Organ transplants are increasingly successful, and many kidney transplant recipients continue to lead long, fulfilling lives following surgery. Occasionally, a transplant recipients immune system may detect something in the system, due in large part to cytotoxic antibodies, a substance in the blood, which can cause the recipients body to reject the donated kidney. Specialists will conduct extensive tests to minimize the risk of organ rejection in advance of the transplant surgery, and will often administer medication following the surgery to reduce this risk further (you can find more information about immunosuppressants further in this section). Patients may also experience acute rejection, an episode where the body detects the foreign object only temporarily. This is common in the first year following transplant, however it can also lead to chronic rejection. Chronic rejection, which is characterized by gradual loss of organ function, is an ongoing concern for transplant recipients because ...
Innes, H. A., McDonald, S. A., Dillon, J. F., Allen, S., Hayes, P. C., Goldberg, D., Mills, P. R., Barclay, S. T., Wilks, D., Valerio, H., Fox, R., Bhattacharyya, D., Kennedy, N., Morris, J., Fraser, A., Stanley, A. J., Bramley, P. & Hutchinson, S. J. Aug 2015 In : Hepatology. 62, 2, p. 355-364 10 p.. Research output: Contribution to journal › Article ...
CCR5 has been implicated in the regulation of Th1 lymphocyte function (14). CCR5 is the receptor for the proinflammatory chemokines: RANTES, MIP-1α, and MIP-1β (1). It has been shown that CCR5 and RANTES may play important roles in the pathogenesis of acute lung and renal allograft rejection in humans (9). Gao et al. (8) recently demonstrated that targeting CCR5 prolongs cardiac allograft survival in the mouse model. However, given a lack of intragraft IL-4, IL-5, or IL-10 mRNA in CCR5−/− recipients, no evidence for immune deviation toward an intragraft Th2 regulatory cell population was apparent in their study (8). Studies on murine and human heart and skin models indicate that, in the process of acute rejection, the temporal expression of critical chemokines varies among different organs or tissues. For instance, CXCR3 and its ligands, IP-10 and Mig, are expressed by the T-cells infiltrating lung and heart allografts and mediate chemotaxis of T-cells at sites of rejection (15,16) (17). ...
In addition, rejection may be a problem at any time for people who take kidney transplant. Although the effects of anti-rejection medicine has been improving, it can not treat chronic rejection, which once occurring, and it will gradually lead to lose renal function and they will have to take dialysis again. Further more, a long time application of anti-rejection medicine can decline the bodys immune capacity, which can lead to toxicity to liver and kidney, hyperglycemia, osteoporosis. Besides, infection is the main factor causing rejection or death. While their incidence of cancer may be several times as much as the healthy peoples ...
London, May 25 (IANS) A team of British researchers has developed a new technique to grow the blood vessels using cells from the patient to cut down significantly the risk of transplant rejection. "A major challenge in tissue engineering and regenerative medicine is providing the new tissue with a network of blood vessels and linking this to the patients existing blood supply. This is vital for the tissues survival and integration with adjacent tissues," said Giordano Pula from University of Bath.. But the shortage of adequate patient-derived scaffolds that can support blood vessel growth has been a major limitation for regenerative medicine and tissue engineering.. Other methods only allow limited formation of small blood vessels such as capillaries which makes tissue less likely to successfully transplant into a patient. This led the researchers from the University of Bath and Bristol Heart Institute to start the pioneering research.. "By embedding endothelial progenitor cells (EPCs) in a ...
14 Feb 2012. These encouraging results may lead to a novel treatment protocol for high-risk corneal graft recipients who are more likely to reject the graft ...
The introduction of the immunosuppressive agent, tacrolimus, has led to a significant reduction in acute rejection of liver transplants. However, little is known about the rate of chronic rejection for liver transplant patients taking tacrolimus.. Dr Ashok Jain and colleagues in Pittsburgh, USA, evaluated the development of chronic rejection in 1,048 consecutive adults receiving primary liver allografts.. After a mean follow up of 77.3 months 32 of the 1,048 patients (3.1%) developed chronic rejection.. Patients were divided into 3 groups in order to assess the risk of chronic rejection depending on primary diagnosis. ...
Improved success in clinical renal transplantation is dependent upon optimal matching of donor and recipient tissue antigens, and upon more effective and less t
Cross-dressing of recipient cells with allogeneic MHC molecules carried by donor exosomes occurs regularly after transplantation. However, it is still unknown whether this phenomenon plays a significant role in the T cell alloresponse and allograft rejection.. In this study, we tested whether GW4869, a sphingomyelase 2 inhibitor known to inhibit cell release of exosomes, could prevent allo-MHC cross-dressing and thereby impair the alloresponse and rejection process in transplanted mice. To test this hypothesis, we administered GW4869 (60ug/mouse/dose) to B6 or BALB/c donors on days -5, -3, -1 pre-transplantation. We transplanted fully mismatched recipients with skin, heart, or islet allogeneic grafts and administered GW4869 on days 1, 3, and 5 post transplantation. Imaging flow cytometry of leukocytes from recipients' draining lymphoid organs showed greater than 33% reduction of the frequency of recipient cells cross-dressed with donor MHC in GW4869 treated mice compared to control ...
PTLD commonly involves the graft itself in addition to affecting extranodal locations such as the gastrointestinal tract and the brain. In allograft biopsies the main differential diagnosis of PTLD includes the most severe forms of acute allograft rejection. Dense inflammatory infiltrates are common in acute rejection. These infiltrates are usually mixed and include variable proportions of activated lymphocytes (immunoblasts) that may show significant cytologic atypia. Reduction in immunosuppression is of paramount importance in the treatment of PTLD, whereas misdiagnosis of these lesions as rejection reactions will lead to the contrary. For the same reasons, delay in the correct diagnosis of PTLD may lead to potentially life-threatening progression of the disease. The mortality that may be associated with PTLD is particularly unacceptable in the situation of elective organ transplantation (i.e. kidney, pancreas). The situation is different in the case of patients with liver or heart/lung ...
TY - JOUR. T1 - Donor-specific unmodified bone marrow transfusion does not facilitate intestinal engraftment after bowel transplantation in a porcine model. AU - Pirenne, Jacques. AU - Gruessner, Angelika C.. AU - Benedetti, Enrico. AU - Troppmann, Christoph. AU - Nakhleh, Raouf E.. AU - Uckun, Fatih M.. AU - Gruessner, Rainer W G. PY - 1997/1. Y1 - 1997/1. N2 - Background. The immunosuppression required to prevent rejection of intestinal transplants causes a high rate of infection and lymphoma. It is crucial that immunomodulatory strategies be developed to facilitate intestinal engraftment. Methods. We prospectively examined the effect of unpurified donor-specific bone marrow transfusions (DSBMTs) on rejection, infection, graft-versus-host disease (GVHD), and survival after intestinal transplantations in 44 Yorkshire Landrace pigs. Four groups that difference according to presence or absence of treatment with FK506 and DSBMT were analyzed. Results. In nonimmunosuppressed pigs, DSBMTs had no ...
Letter Re: Safety of Combination Biologic and Antirejection Therapy Post-liver Transplantation in Patients With Inflammatory Bowel Disease ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Research Interest. Regulation of graft rejection by direct and indirect alloreactivity pathways Solid organ transplantation remains the treatment of choice for numerous patients with kidney, heart, and lung diseases. The recognition of allogeneic major histocompatibility complex antigens by T lymphocytes, a phenomenon called alloreactivity, is essential to initiate the immune responses responsible for graft rejection during organ transplants and it remains a major hindrance to the success of transplantation. In spite of the progress made in the recent years on the description of T cell recognition, the molecular basis of alloreactivity remains elusive. Moreover, little is known about the actual contribution of allorecognition to the physiology of graft rejection in vivo. Two pathways of alloreactivity have been described. Indirect alloreactivity corresponds to the classical pathway of antigen presentation, as the allogeneic MHC molecules are degraded and the peptides derived from these molecules ...
Wang H-TL, Cipullo R, França JID, Finger MA, Rossi Neto JM, Correia E de B, Dinkhuysen JJ, Hirata MH. Intragraft vasculitis and gene expression analysis: association with acute rejection and prediction of mortality in long-term heart transplantation [Internet]. Clinical Transplantation. 2018 ; 32( 10): 1-10 art. e13373.Available from: http://dx.doi.org/10.1111/ctr. ...
drugsupdate.com - Indias leading online platform for Doctors and health care professionals. Updates on Drugs, news, journals, 1000s of videos, national and international events, product-launches and much more...Latest drugs in India, drugs, drugs update, drugs update
In chronic liver rejection lymphocyte mediated processes lead to chronic inflammation, necrosis and repair mechanisms. The aim of the present study was to investigate the expression of apoptosis related proteins (FAS/APO-1, FAS-L, Bcl-2, Bax, TNF-α, and INF-γ). ApopTag reaction and immunohistochemistry were performed on liver samples of chronically rejected allografts and compared with normal donor livers. In chronic rejection, apoptosis was detected in pericentral hepatocytes and in the biliary epithelium. Bcl-2 was strongly expressed on lymphocytes around the bile ducts, but not on the biliary epithelium itself. Bax, FAS, TNF-α and INF-γ were present in pericentral areas. T-cells showed up around bile ducts, whereas macrophages around pericentral areas. In pericentral areas apoptosis seems to be fostered through TNF-α and INF-γ and by the lack of Bcl-2. Based on these results both downregulation and upregulation of apoptotic proteins can be observed in chronic liver allograft rejection: ...
A diabetes drug currently undergoing development could be repurposed to help end transplant rejection, without the side-effects of current immunosuppressive drugs, according to new research by Queen Mary University of London ...
As far as I know, you should be able to detect both ab and cytokines from serum as well as from plasma. However, at least cytokines can be difficult if not impossible to detect that way due to their small concentrations, and the results can be quite ambiquous. Anyways, if you manage to detect cytokines, Id probably go for Th1 vs. Th2 cytokines for example, to evaluate the function of T-cells, which are responsible for the graft rejection. Antibodies should be more straightforward to measure, probably with some ELISA system ...
Rivera A, Chen CC, Ron N, Dougherty JP, Ron Y. Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. Int Immunol 2001; 13: 1583-1593 ...